Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2024-03-12 00:00:00 ET · period of report 2024-03-08 · accession 0000950170-24-030479 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-03-12 | 2024-03-08+ | DYN | Brumm Joshua T | CEO, Pres, Dir | M - OptEx | $5.54 | +413.3K | 604.4K | +216% | +$2.29M |
| DMT | 2024-03-12 | 2024-03-08+ | DYN | Brumm Joshua T | CEO, Pres, Dir | S - Sale+OE | $25.89 | -429.7K | 554.4K | -44% | -$11.13M |
| DMT | 2024-03-12 | 2024-03-08+ | DYN | Brumm Joshua T | CEO, Pres, Dir | M - OptEx | $0.00 | -413.3K | 133.3K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | M | A | 153,931 | $5.54 | 708,316 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-08 | M | A | 209,412 | $5.54 | 917,728 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-08 | S | D | 202,238 | $25.30 | 715,490 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| 4 | Common | Common Stock | 2024-03-08 | S | D | 160,670 | $26.72 | 554,820 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive. |
| 5 | Common | Common Stock | 2024-03-11 | S | D | 8,618 | $25.93 | 537,998 | D | — | — | (F8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive. (F9) Includes 513,913 unvested RSUs. |
| 6 | Common | Common Stock | 2024-03-11 | M | A | 50,000 | $5.54 | 604,385 | D | — | — | |
| 7 | Common | Common Stock | 2024-03-11 | S | D | 40,072 | $25.42 | 564,313 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive. |
| 8 | Common | Common Stock | 2024-03-11 | S | D | 9,928 | $26.10 | 554,385 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive. |
| 9 | Common | Common Stock | 2024-03-11 | S | D | 7,769 | $26.12 | 546,616 | D | — | — | (F6) Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive. |
| 10 | Common | Common Stock | 2024-03-08 | S | D | 435 | $27.38 | 554,385 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive. |
| 11 | Derivative | Stock option (right to buy) | 2024-03-08 | M | D | 153,931 | $0.00 | 0 | D | $5.54 · — to 2030-07-30 | 153,931 Common Stock | (F10) The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |
| 12 | Derivative | Stock option (right to buy) | 2024-03-11 | M | D | 50,000 | $0.00 | 83,269 | D | $5.54 · — to 2030-07-30 | 50,000 Common Stock | (F11) The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. |
| 13 | Derivative | Stock option (right to buy) | 2024-03-08 | M | D | 209,412 | $0.00 | 133,269 | D | $5.54 · — to 2030-07-30 | 209,412 Common Stock | (F11) The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. |